

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE FAX RECEIVED

In re application of: Raulet et al.

Group Art Unit: 1642

JAN 0 9 2003

Serial No. 09/871,491

Examiner: Harris, A.

GROUP 1600

Filed: May 31, 2001

Attorney Docket No. B01-088

For:

Tumor Therapy

CERTIFICATE OF TRANSMISSION

I hereby certify that this corr is being transmitted by facsimile to the

Comm for Patents at 703-872-9306 on January 8, 2003.

Signature

RESPONSE

The Commissioner for Patents Washington, DC 20231

Dear Examiner Harris:

Thank you for the Office Action dated Dec. 16, 2002. Please enter these amendments:

IN THE CLAIMS

Please cancel the pending claims and add new claims 19-38 as follows:

19. A method for inhibiting metastatic prostate tumor growth in a maximalian host expressing native NKG2D and determined to have a metastatic prostate tumor arising in situ and comprising prostate tumor cells, the method comprising steps:

administering to the mammalian host a composition comprising an NKG2D-binding agent, wherein the NKG2D-binding agent is multivalent, wherein the administering step is effective to inhibit growth of the tumor; and

detecting a resultant inhibition of growth of the tumor by evaluating growth of the tumor.

- 20. A method according to claim 19, wherein the administering is remote from the tumor.
- 21. The method of claim 19, wherein the agent comprises an NKG2D-specific antibody.

